rani therapeutics holdings inc - RANI

RANI

Close Chg Chg %
0.87 0.01 0.83%

Closed Market

0.87

+0.01 (0.83%)

Volume: 531.88K

Last Updated:

Sep 8, 2026, 4:00 PM EDT

Company Overview: rani therapeutics holdings inc - RANI

RANI Key Data

Open

$0.87

Day Range

0.86 - 0.90

52 Week Range

0.45 - 3.87

Market Cap

$100.42M

Shares Outstanding

115.43M

Public Float

87.99M

Beta

0.71

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.27

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

674.13K

 

RANI Performance

1 Week
 
0.83%
 
1 Month
 
10.16%
 
3 Months
 
14.79%
 
1 Year
 
74.64%
 
5 Years
 
-95.68%
 

RANI Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About rani therapeutics holdings inc - RANI

Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company was founded by Mir Imran on February 21, 2012 and is headquartered in San Jose, CA.

RANI At a Glance

Rani Therapeutics Holdings, Inc.
2051 Ringwood Avenue
San Jose, California 95131
Phone 1-408-457-3700 Revenue 1.63M
Industry Biotechnology Net Income -29,673,000.00
Sector Health Technology 2025 Sales Growth 58.852%
Fiscal Year-end 12 / 2026 Employees 71
View SEC Filings

RANI Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 54.676
Price to Book Ratio 3.992
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -1.395
Enterprise Value to Sales 31.964
Total Debt to Enterprise Value 0.083

RANI Efficiency

Revenue/Employee 23,000.00
Income Per Employee -417,929.577
Receivables Turnover 0.755
Total Asset Turnover 0.034

RANI Liquidity

Current Ratio 4.209
Quick Ratio 4.209
Cash Ratio 3.939

RANI Profitability

Gross Margin 44.887
Operating Margin -2,345.989
Pretax Margin -2,507.655
Net Margin -1,817.085
Return on Assets -62.302
Return on Equity -169.55
Return on Total Capital -79.493
Return on Invested Capital -116.401

RANI Capital Structure

Total Debt to Total Equity 13.081
Total Debt to Total Capital 11.568
Total Debt to Total Assets 7.366
Long-Term Debt to Equity 8.276
Long-Term Debt to Total Capital 7.319
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Rani Therapeutics Holdings Inc - RANI

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- - 1.03M 1.63M
-
Sales Growth
- - -100.00% +58.85%
-
Cost of Goods Sold (COGS) incl D&A
1.31M 822.00K 1.03M 900.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.31M 822.00K 1.03M 900.00K
Depreciation
1.31M 822.00K 1.03M 900.00K
Amortization of Intangibles
- - - -
-
COGS Growth
- -37.35% +25.06% -12.45%
Gross Income
- (1.31M) (822.00K) 733.00K
Gross Income Growth
- - +37.35% +100.00%
-
Gross Profit Margin
- - - +44.89%
-
2022 2023 2024 2025 5-year trend
SG&A Expense
62.14M 65.28M 49.60M 39.04M
Research & Development
36.61M 39.62M 26.68M 20.20M
Other SG&A
25.53M 25.65M 22.92M 18.84M
SGA Growth
+15.46% +5.05% -24.02% -21.28%
Other Operating Expense
- - - -
-
Unusual Expense
- - 3.71M 576.00K
-
EBIT after Unusual Expense
(63.45M) (66.10M) (53.31M) (38.89M)
Non Operating Income/Expense
1.25M 3.30M 1.76M 827.00K
Non-Operating Interest Income
1.25M 3.30M 1.76M 827.00K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
1.07M 5.08M 5.03M 2.89M
Interest Expense Growth
+129.83% +374.79% -1.02% -42.56%
Gross Interest Expense
1.07M 5.08M 5.03M 2.89M
Interest Capitalized
- - - -
-
Pretax Income
(63.27M) (67.88M) (56.58M) (40.95M)
Pretax Income Growth
-19.28% -7.28% +16.64% +27.63%
Pretax Margin
- - -5,504.28% -2,507.65%
-
Income Tax
- - - 70.00K
-
Income Tax - Current - Domestic
- - - 70.00K
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(63.34M) (67.88M) (56.58M) (40.95M)
Minority Interest Expense
(32.76M) (33.91M) (26.57M) (11.28M)
Net Income
(30.59M) (33.97M) (30.02M) (29.67M)
Net Income Growth
-267.16% -11.06% +11.63% +1.15%
Net Margin Growth
- - -2,920.04% -1,817.09%
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(30.59M) (33.97M) (30.02M) (29.67M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(30.59M) (33.97M) (30.02M) (29.67M)
EPS (Basic)
-1.2843 -1.3319 -1.0542 -0.4486
EPS (Basic) Growth
-203.90% -3.71% +20.85% +57.45%
Basic Shares Outstanding
23.82M 25.50M 28.48M 66.14M
EPS (Diluted)
-1.2843 -1.3319 -1.0542 -0.4486
EPS (Diluted) Growth
-203.90% -3.71% +20.85% +57.45%
Diluted Shares Outstanding
23.82M 25.50M 28.48M 66.14M
EBITDA
(62.14M) (65.28M) (48.57M) (37.41M)
EBITDA Growth
-21.60% -5.05% +25.59% +22.98%
EBITDA Margin
- - -4,724.90% -2,290.88%
-

Snapshot

Average Recommendation BUY Average Target Price 7.50
Number of Ratings 5 Current Quarters Estimate -0.048
FY Report Date 09 / 2026 Current Year's Estimate -0.175
Last Quarter’s Earnings -0.04 Median PE on CY Estimate N/A
Year Ago Earnings -0.45 Next Fiscal Year Estimate -0.19
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 4 4 4
Mean Estimate -0.05 -0.05 -0.18 -0.19
High Estimates -0.04 -0.04 -0.17 -0.17
Low Estimate -0.05 -0.06 -0.18 -0.20
Coefficient of Variance -10.53 -16.33 -3.30 -7.44

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 5 4
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Rani Therapeutics Holdings Inc in the News